Tools for Practice Outils pour la pratique


#201 Any Other “Doobie”ous Effects of Medical Cannabinoids?


CLINICAL QUESTION
QUESTION CLINIQUE
 Besides pain, are medical cannabinoids effective for other conditions?

BOTTOM LINE
RÉSULTAT FINAL
 For most conditions (example anxiety), cannabinoid evidence is sparse (at best), low quality and non-convincing. Dronabinol/nabilone improve control of nausea/vomiting post-chemotherapy for 1 in 3 users over placebo. Nabiximols likely improve multiple sclerosis spasticity ≥30% for ~1 in 10 users over placebo. Patients’ preference for cannabinoids exceeds cannabinoids effectiveness. 


CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

 Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session


EVIDENCE
DONNÉES PROBANTES
 Two comprehensive systematic reviews (SR) suggest reasonable evidence for nausea/vomiting (from chemotherapy) and spasticity.1,2 In other conditions, high-level evidence is too sparse, low quality and/or negative. Examples:  
  • Glaucoma: One Randomized Controlled Trial (RCT) (6 patients): No benefit.1,2   
  • Anxiety: One RCT (24 patients) on simulated public speaking: More improvement on mood scale.2    
Nausea/vomiting (mostly dronabinol/nabilone 1-day post-chemotherapy): Seven SRs of 5-30 RCTs (635-1,772 patients).1,3-8 Statistically significant unless indicated.  
  • Meta-analyses for control of nausea/vomiting.1,5,7
    • Versus placebo:3 47% versus 13%, Number Needed to Treat (NNT)=3.
    • Versus neuroleptic:3 31% versus 16%, NNT=7. 
    • Others find similar.1,5,7  
  • Patient preference exceeds effectiveness: NNT=2 versus placebo and NNT=3 versus neuroleptic.6,8   
    • Suggests something other than effectiveness influences preference. 
  • Not chemotherapy-related: 
    • Palliative care (cancer/HIV): One SR, symptoms unchanged.6   
    • Post-Op: One RCT (60 patients), nabilone versus metoclopramide: No difference.9 
  • No clear difference between nabilone or dronabinol.5,7 
Spasticity (mostly nabiximol, ~70 days, multiple sclerosis): Five SRs of 3-17 RCTs (481-2,280 patients), versus placebo.1,10-13    
  • Meta-analysis of meaningful change in symptoms:3 50% versus 35%, NNT=7.  
    • Others find similar.1,10   
  • ≥30% improvement in spasticity:10 35% versus 25%, NNT=10.   
  • Four meta-analyses of mean change in scale:  
    • Two meta-analyses:1,10 1.3 versus 0.97 placebo (clinical significance ~1.1).10   
    • Two meta-analyses: Not statistically significant.1,13   
Context:   
  • Issues: 
    • Quality often poor.1   
    • Many studies small/short.1,8  
    • Blinding not possible: Example, 85-95% of patients and clinicians know who’s on cannabinoids.8,14   
  • Approved indication:  
    • Nabilone (Cesamet™): Chemotherapy-induced nausea/vomiting.   
    • Nabiximol (Sativex™): Adjunctive therapy for spasticity of multiple sclerosis and pain from multiple sclerosis or cancer.     
  • For pain15 and adverse events16 see Tools for Practice #199 and #200.   
  • Although evidence for seizure is sparse, one RCT suggests potential in children with Dravet epilepsy.17   

Latest Tools for Practice
Derniers outils pour la pratique
program image
Adrienne J Lindblad BSP ACPR PharmD

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Read Lire 0.25 credits available Crédits disponibles
program image
Jennifer Potter MD CCFP

#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)

What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
Read Lire 0.25 credits available Crédits disponibles
program image
Betsy Thomas BScPharm

#375 Pharm for Fibro: Can antidepressants ease the pain?

Do antidepressants reduce pain in patients with fibromyalgia?
Read Lire 0.25 credits available Crédits disponibles
December 11, 2017

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session
Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • Jamil Ramji BSc BSP ACPR
  • Danielle Perry RN

1. Whiting PF, Wolff RF, Deshpande S, et al. JAMA. 2015; 313(24):2456-73.

2. National Academies of Sciences, Engineering, and Medicine. 2017. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press. doi: 10.17226/24625. 2017. Available at: https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state. Last Accessed: September 4, 2017.

3. Allan GM, Finley CR, Ton J, et al. Can Fam Physician, 2018, in press.

4. Cotter J. Oncol Nurs Forum. 2009; 36(3):345-52.

5. Machado Rocha FC, Stefano SC, et al. Eur J Cancer Care. 2008; 17(5):431-43.

6. Mucke M, Carter C, Cuhls H, et al. Der Schmerz. 2016; 30(1):25-36.

7. Smith LA, Azariah F, Lavender VT, et al. Cochrane Database Syst Rev. 2015;11:CD009464.

8. Tramer MR, Carroll D, Campbell FA, et al. BMJ. 2001; 323(7303):16-21.

9. Canadian Agency for Drugs and Technologies in Health. Nabilone for Non-chemotherapy Associated Nausea and Weight Loss due to Medical Conditions. Ottawa, ON: CADTH, 2014. Available at: https://cadth.ca/sites/default/files/pdf/htis/2017/RC0905%20Nabilone%20for%20Non-Chemotherapy%20Nausea%20and%20Weight%20Loss%20Final.pdf. Last Accessed: September 4, 2017.

10. Wade DT, Collin C, Stott C, et al. Mult Scler. 2010; 16(6):707-14.

11. Koppel BS, Brust JC, Fife T, et al. Neurology. 2014; 82(17):1556-63.

12. Lakhan SE, Rowland M. BMC Neurol. 2009; 9:59.

13. Meza R, Pena J, Garcia K, et al. Medwave. 2017; 17(Suppl1):e6865.

14. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids for the management of neuropathic pain: Review of clinical effectiveness. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2010. (CADTH 2010b)

15. Allan GM, Finley CR, Hauptman R, et al. Tools for Practice. Available at: https://www.acfp.ca/wp-content/uploads/tools-for-practice/1510681044_tfp199mmandpainfv.pdf. Last accessed: December 8, 2017.

16. Allan GM, Ton J. Tools for Practice. Available at: https://www.acfp.ca/wp-content/uploads/tools-for-practice/1511480622_tfp200harmsmmfv.pdf. Last accessed: December 8, 2017.

17. Devinsky O, Cross JH, Laux L, et al. N Engl J Med. 2017 May 25; 376(21):2011-20.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.